Citius Pharmaceuticals Inc

CTXRNASDAQ · USD
0.61USD+0.03 (+5.28%)
312

Citius Pharmaceuticals Inc (CTXR) Straddle

No qualifying straddle setups were found for CTXR in the prior session.

Read more

Trading a CTXR straddle lets you take a pure volatility position on Citius Pharmaceuticals Inc without committing to a direction. Citius Pharmaceuticals Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate CTXR straddle pricing in real time and find the moments when expected moves are mispriced.

A long straddle on CTXR profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Citius Pharmaceuticals Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the CTXR straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma.

Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Earnings, product cycles, macro prints — any time volatility itself is the trade, the CTXR straddle is the cleanest expression of that view. Our scanner prices every CTXR straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a CTXR straddle into a catalyst or short a CTXR straddle to harvest decay, the options straddle setups that matter are all in one place.

No illustrative rows to display.

As of September 21, 2026

Find the right straddle before volatility moves

Track CTXR straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.

Start your 14-day free trial